Back to list

Viz.ai

AI-powered care coordination platform for time-sensitive medical conditions
Healthcare 📍 San Francisco, CA Founded 2016
Current Valuation
$1.2B
as of 2022-Q2
UNICORN

IPO Outlookrumored

Is Viz.ai going public in 2026?
An IPO is rumored for 2026, with nothing filed. Viz.ai remains private and the date is not the company's.
What is Viz.ai's valuation in 2026?
Viz.ai is valued at $1.2B as of 2022-Q2, set by its Series D ($100M, Apr 2022). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Viz.ai filed an S-1?
No public S-1 is on file for Viz.ai as of 08/23/2026; the IPO is rumored.
Who are Viz.ai's investors?
Viz.ai's investors include Tiger Global, Insight Partners, Kleiner Perkins, Greenoaks Capital, Threshold Ventures, GV.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Viz.ai operates a clinical AI platform that detects time-sensitive conditions — large-vessel-occlusion stroke, pulmonary embolism, aortic aneurysm — on CT and MRI scans and instantly mobilizes specialist care teams. The company was valued at $1.2 billion in its 2022 Series D and has expanded across more than 1,500 U.S. hospitals. Sacra estimates roughly $40M in 2023 revenue with around 74% year-over-year growth, positioning Viz.ai as a frequently cited 2026 IPO candidate in healthcare AI.

Company Profile

CEO
Chris Mansi
Founded
2016
HQ
San Francisco, CA
Employees
~400
Total Raised
$250M
Est. Revenue
$40M (2023)
Growth
~74% YoY
Last Round
Series D — $100M (Apr 2022) · Lead: Tiger Global
IPO Status
rumored

Fundraising Status

Series D · $100M · 4y 4mo ago
rumoredTotal raised $250M

Latest Funding Round

RoundAmountDateLead InvestorPost-Money
Series D$100MApr 2022Tiger Global

Vertical Intelligence — AI / ML

No verified Hugging Face organization found for Viz.ai — no attributable open-model footprint. Closed-weights labs are common; this is a distribution signal, not a capability judgment.
Checked huggingface.co as of 2026-08-19. Re-checked weekly.

Talent Signal

Hiring trend
First snapshot
trend accrues with monthly sweeps
Open roles
14
via ashby
Product-build share
21%
engineering, research, product, design
Trajectory
strengthening
go-to-market push — Only 21% of open roles build product — hiring is concentrated in sales/marketing/ops (6 of 14 open roles are sales).
Recent senior hire: 1 senior hire (CRO).
Open roles by month
Open roles by month14Aug '26
Open roles by function
Open roles by functionSales & GTM6Other4Engineering2Clinical & Science1Marketing1
product-building   go-to-market / G&A
Key Executive Moves
INJallel HarratiCRO · 2026-08-16
From trusted-source news extraction (deep-enrich pipeline); dates approximate publication, not effective date.
Senior Clinical Specialist - CardiologySenior Platform Engineer Senior Algorithm DeveloperBusiness Development Senior DirectorCustomer Success Leader, West RegionProject Manager
Counted from Viz.ai's live job board as of 2026-08-17; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.

Founders & Key People

Chris MansiDavid Golan

Investors

Tiger Global · Insight Partners · Kleiner Perkins · Greenoaks Capital · Threshold Ventures · GV

Products

  • Viz Stroke (LVO detection)
  • Viz Cardio (pulmonary embolism, aneurysm)
  • Viz Subdural and ICH
  • Viz Connect (care coordination)
  • Viz HCM, RV/LV

Competitors

Aidoc · RapidAI · Rad AI · Caption Health
Healthcare AIMedical ImagingStroke CareUnicorn
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2022-Q2. Refreshed quarterly.